Latest Headlines

Latest Headlines

Ranbaxy shipping generic Lipitor from new Indian plant

Ranbaxy Laboratories has a new FDA-approved plant in India from which it is shipping a generic Lipitor to the U.S.

Astellas extends Lipitor marketing deal with Pfizer

Astellas Pharma extended its deal with Pfizer ($PFE) to market the cholesterol drug Lipitor in Japan.

Sanofi, Regeneron report stellar LDL drug data as race heats up

Sanofi and Regeneron today noted that their rival PCSK9 inhibitor triggered a significant drop in LDL levels among patients with a high level of the "bad" kind of cholesterol.

After slashing jobs, Pfizer CEO Ian Read draws $25M

As Bloomberg reports, the Pfizer board rewarded CEO Ian Read with a $25 million paycheck.

Health plans sue Big Pharma over co-pay coupons

Pharma's co-pay discounts have their fans--patients, certainly, but they also have their detractors.

Copycat Lipitor hits in 4 EU countries

Ranbaxy Laboratories launched its version of the cholesterol blockbuster Lipitor in Italy, Sweden and the Netherlands, while its German subsidiary unveiled the Lipitor copy in that country.

Merck's new cholesterol combo faces delay

Merck's ($MRK) bid to get a combination Zetia- Lipitor cholesterol pill on the market faces a new hurdle. The FDA wants to see more data on the pill. The company hopes ongoing studies will fill...

How worrisome is the statin-diabetes link?

The FDA's cautionary word on statin use has stirred up a back-and-forth risk-benefits debate. When the agency announced last week that it would highlight the risk of Type 2 diabetes on the cholesterol drugs' labels, some prominent heart doctors issued their own warnings: Don't worry too much about that risk. For most patients, the heart benefits of statins outweigh the "small" risk of developing diabetes.

FDA flags diabetes risks with statin drugs

Big-selling cholesterol drugs got new warnings on their labels, but the cautionary language about blood sugar and memory loss isn't expected to diminish their popularity much.

WellPoint to drop branded Lipitor from its formulary

Lipitor just got shot down by a healthcare plan. As The Wall Street Journal reports, WellPoint ($WLP) is planning to stop covering Pfizer's ($PFE) brand-name cholesterol drug April 1, favoring its